NCT03829449View on ClinicalTrials.gov

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

PHASE3TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

August 29, 2020

Study Completion Date

August 29, 2020

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

rVA576

The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).

Trial Locations (1)

02-776

Instytut Hematologii i Transfuzjologii, Warsaw

Sponsors

Lead Sponsor

AKARI Therapeutics
All Listed Sponsors
lead

AKARI Therapeutics

INDUSTRY